1.Executive Summary
Hope Returned, but Mostly Through Scarcity
Research window
2026-06-01 to 2026-06-30
Data vintage
Retrospective edition, researched through 2026-08-05
Linked sources
27 primary and attributable references
Mood 2.6 / 10 · Bearish — a shimmer of hope
+1.0 vs. MayJune was the first month since the Iran shock in which the sector's near-term mood improved materially. The ifo chemical business climate rose by more than twelve points. Current conditions nearly normalized relative to the preceding lows. Producer energy prices eased. Export expectations became less negative.
The reason limits the celebration. Missing imports and disrupted Asian production redirected some orders toward European suppliers. Scarcity improved German capacity use precisely because competitors were constrained. That can support margins for a quarter. It does not prove that the German cost base has become competitive.
Monitoring note. June statistics released on July 1 and July 20 are used retrospectively. The Mood Index weights demand and output 40%, energy and inputs 20%, company decisions 20%, regulation 10%, and capital-market narrative 10%.
Source scope includes VCI, Destatis, and the Federal Ministry for Economic Affairs and Energy (BMWE, formerly BMWK). No ministry production series superseded the VCI/Destatis sector data in this window.
Mood Index: 2.6 / 10 — Bearish, a shimmer of hope
Change from May: +1.0
| Indicator | June reading | Interpretation |
|---|---|---|
| ifo chemical business climate | -17.8 | Strong improvement from May's -30.2 |
| ifo current situation | -2.9 | Near-neutral operating assessment |
| ifo expectations | -31.5 | Future remained deeply negative |
| Export expectations | -4.8 | Less negative, not expansionary |
| Producer energy prices | -1.8% m/m; +0.4% y/y | Monthly easing after spring shock |
| Basic chemical prices | +12.9% y/y | Scarcity and feedstock inflation passed through |
Top three events
- Evonik announced 3,200 additional job reductions through 2029. About 2,150 were assigned to Germany, and the Witten site was slated for closure.
- Merck KGaA agreed to acquire Bio-Techne for $11.3 billion. The transaction shifted capital toward global life-science tools and away from commodity exposure.
- Bayer won a landmark Roundup preemption case at the US Supreme Court. The legal event produced an extraordinary share-price re-rating, although it did not eliminate all litigation risk.
Strategic conclusion
June improved the cycle but weakened the location case. Temporary demand relief raised the value of existing German assets. Evonik's job decision showed that management still expected the structural cost gap to persist beyond the special cycle.
2.Macroeconomic & Regulatory Landscape
Demand, energy, policy, and the Standort D cost stack
Production, sales, and employment
The latest hard-data baseline remained the VCI's first quarter: chemical output +2.0% quarter on quarter but -4.3% year on year, sector sales €50.9 billion and -5.4% year on year, utilization 75.1%, and employment 471,500.
June's ifo survey then captured a notable current improvement. The chemical business climate rose to -17.8 from -30.2. Current conditions improved from -17.5 to -2.9. Export expectations rose to -4.8 from about -16. Expectations for the overall business remained deeply negative at -31.5.
That divergence is economically coherent. Customers substituted European product for missing imports and replenished inventories. Plants shipped more today while expecting the advantage to fade tomorrow. A recovery driven by the disappearance of competitors' supply is real income, but not a new equilibrium.
Employment evidence remained unambiguously weak. Evonik's June announcement alone assigned 2,150 future reductions to Germany. It came in addition to a program eliminating 2,800 positions by the end of 2026.
Sources: VCI Q1 2026 report, ifo June chemical climate, Reuters — Evonik job cuts
Energy and inputs
Producer energy prices fell 1.8% from May and were only 0.4% above the prior year. Gas prices were 1.8% lower year on year, electricity 4.2% lower. Oil-linked chemistry remained the exception. Mineral-oil products were 23.7% more expensive, and naphtha 38.1%.
The divergence passed into chemical product prices. Basic chemicals were 12.9% more expensive year on year, and fertilizers 17%. Margin outcomes depended on whether a producer could pass higher naphtha costs into product prices faster than customers could switch or defer purchases.
The industrial electricity scheme had entered its implementation phase, but no sector-wide realized relief figure was available in June. Strompreiskompensation remained relevant for eligible indirect carbon costs. Industry complaints therefore shifted from the existence of policy to its coverage, conditions, and administrative burden.
Sources: Destatis producer prices, June, Federal industrial electricity explainer
Green Deal and REACH
On June 1, the European Commission adopted a roadmap for phasing out animal testing in chemical safety assessments. More than 30 recommendations addressed methods, data, validation, and regulatory acceptance. For the sector, the innovation challenge is not merely developing alternative methods; regulators must accept them across jurisdictions and use cases.
The roadmap fits the Green Deal's safer-chemicals agenda but also offers a potential efficiency gain. Better in-silico and non-animal methods could reduce development time if acceptance is coordinated. Fragmented validation would produce the opposite result.
Sources: European Commission — animal-testing phase-out roadmap, European Commission REACH overview
3.Corporate Movers & Shakers
Eight-company decision ledger and Standort D implications
| Company | June event | Standort D reading |
|---|---|---|
| BASF | Closed the majority sale of Coatings to Carlyle on June 30 at €7.7bn enterprise value; retained 40% | Portfolio divestment generated cash but removed a major business from full ownership |
| Bayer | US Supreme Court victory in the Durnell Roundup case | Litigation risk fell; no new German capacity decision |
| Covestro | Squeeze-out implementation continued | Ownership transition, no fresh June plant closure |
| Evonik | 3,200 additional global jobs to go in 2027–2029, 2,150 in Germany; Witten site to close | Strongly negative Standort D decision |
| Lanxess | No new June closure or profit warning | March savings program remained the baseline |
| Wacker Chemie | No new June earnings release; PACE implementation continued | German job-reduction program unchanged |
| Henkel | No material June earnings or closure announcement | Integration of acquired businesses continued |
| Merck KGaA | Agreed to acquire Bio-Techne for $11.3bn (€9.9bn) | Global science-tools expansion; strategic center remained in Darmstadt |
Evonik's program was not a small extension. The company planned to reduce 3,200 jobs worldwide from 2027 to 2029, including 2,150 in Germany, after completing 2,800 reductions by the end of 2026. It also planned to discontinue the polyester business in 2027, close Witten with 266 employees, and affect about 350 positions in Germany and China. The causal claim was structural disadvantage and weak market economics, not a temporary earnings miss.
Merck moved in the opposite strategic direction. The $11.3 billion Bio-Techne agreement targeted life-science tools and anticipated about €140 million of annual synergies by year three. The transaction increased leverage and execution risk, but it also reduced dependence on Europe's energy-intensive bulk cycle.
BASF completed the sale of a majority stake in Coatings to Carlyle. The €7.7 billion enterprise value and retained 40% stake unlocked capital while preserving some upside. It was a portfolio answer to the conglomerate discount, not an investment in German chemical capacity.
Sources: BASF–Carlyle Coatings closing, Bayer Supreme Court victory, Reuters — Evonik restructuring, Merck–Bio-Techne, Reuters — Merck transaction
4.Innovation & Transformation
From pilots and platforms to bankable industrial scale
Evonik began producing a high-performance membrane at a new pilot plant in Marl on June 10. The membrane is designed for more cost-efficient green-hydrogen production. At commercial scale, the pilot could supply membranes for up to 2.5 gigawatts of electrolysis capacity per year, one-quarter of Germany's planned 2030 capacity.
This was the month's most relevant innovation because it connected a material, a German site, and a plausible scaling market. It also exposed the boundary condition: a domestic membrane plant benefits from the hydrogen build-out only if electrolyzer projects reach final investment decisions.
Merck's Bio-Techne transaction represented a different innovation model—buying a global platform rather than building a German process asset. Both models can create value. Only the first directly deepens Standort D production.
Sources: Evonik green-hydrogen membrane pilot, Merck–Bio-Techne
5.Financial, Narrative & Falsification Radar
Equities, analyst evidence, media language, and what would change the view
One-month equity performance
Method: May month-end to June month-end Xetra closes, unadjusted and rounded. Up is above +2%; Down below -2%; otherwise Neutral.
| Company | June performance | Trend |
|---|---|---|
| BASF | -8.0% | Down |
| Bayer | +32.5% | Up |
| Covestro | Takeover-capped near €59.46 | Neutral |
| Evonik | -5.5% | Down |
| Lanxess | -8.1% | Down |
| Wacker Chemie | -8.5% | Down |
| Henkel | +10.3% | Up |
| Merck KGaA | +12.2% | Up |
Bayer's legal victory dominated the month. Merck's acquisition was read as strategically attractive despite financing risk. Chemical cyclicals fell even as the ifo current assessment improved, suggesting investors distinguished temporary order support from sustainable earnings.
Analyst-rating tape
No verified major-bank upgrade or downgrade from Deutsche Bank or Goldman Sachs for the eight companies was found in June. Many results-day and event-driven target-price comments circulated, particularly after Bayer's Supreme Court decision and Merck's acquisition. They are not counted here without a confirmed recommendation change.
Price sources: BASF, Bayer, Covestro, Evonik, Lanxess, Wacker, Henkel, Merck KGaA. Rating source: Deutsche Bank recommendation history.
Headline and Mood Index
Media method: Public headlines and indexed snippets from Handelsblatt, FAZ, CHEManager, and Börsen-Zeitung were reviewed for vocabulary and emphasis. Paywalled or crawler-restricted text was not used as the sole support for a factual claim.
The language moderated from “collapse” to “improvement,” but it did not reach “recovery.” Trade coverage continued to use crisis vocabulary for European capacity. Financial coverage focused on Bayer's legal inflection and Merck's offensive acquisition. The coexistence is instructive: sector crisis and company opportunity are not mutually exclusive.
| Keyword | June signal | Reading |
|---|---|---|
| Deindustrialization | Very high | Evonik's German reductions and Witten closure |
| Recovery | Medium | Current ifo situation and export expectations improved |
| Crisis | High | Expectations remained at -31.5; chemical cyclicals sold off |
Sources: ifo June chemical climate, Labo — why the chemical crisis continues, CHEManager industry coverage
What Would Change the View?
The June improvement becomes a real turn if export expectations cross into positive territory after Asian supply normalizes and if companies cancel rather than execute planned German reductions. A deterioration follows if scarcity pricing fades before input costs do. Hope returned, but its supply-side origin made it fragile.